Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era

Cerrato, Enrico; D’Ascenzo, Fabrizio; Biondi‐Zoccai, Giuseppe; Calcagno, Andrea; Frea, Simone; Marra, Walter Grosso; Castagno, Davide; Omedè, Pierluigi; Quadri, Giorgio; Sciuto, Filippo; Presutti, Davide Giacomo; Frati, Giacomo; Bonora, Stefano; Moretti, Claudio; Gaïta, Fiorenzo

doi:10.1093/eurheartj/ehs471

Cited by 128 publications

(98 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the possible link between antiretroviral (ARV) agents (mainly abacavir) and the development of CVD remains to be elucidated, the introduction of cART seems to have caused a shift from dilated cardiomyopathy with severely reduced ejection fraction to mildly reduced left ventricular function; however, patients with HIV infection are still at increased risk of HF after adjustment for traditional risk factors (1,2). In the cART era, the frequency of systolic and diastolic left ventricular dysfunction has been reported to be 8% and 43%, respectively (6), and the prevalence of heart failure is reportedly %3%, that is, twofold higher than in the non-HIV-infected cohort (1).…”

Section: Epidemiology Of Hf Leading To Ht In Hiv-infected Patientsmentioning

confidence: 99%

An Update on Heart Transplantation in Human Immunodeficiency Virus–Infected Patients

Agüero

Castel

Cocchi

et al. 2016

American Journal of Transplantation

View full text Add to dashboard Cite

Section: Epidemiology Of Hf Leading To Ht In Hiv-infected Patientsmentioning

confidence: 99%

An Update on Heart Transplantation in Human Immunodeficiency Virus–Infected Patients

Agüero

Castel

Cocchi

et al. 2016

American Journal of Transplantation

View full text Add to dashboard Cite

“…On the contrary, BBs positively modify RV dimension and function, with a reduction of its diameter and an improvement of TAPSE, possibly due to a reduction of RV fibrosis [14]. Meantime, probably due to a reduction of right ventricle's stress, it decreased RV inflammation, with a potential protective effect towards fibrosis, a common finding in many pro-inflammatory clinical situation [15], especially for patients with PAH associated with connective disease [16].…”

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 99%

Beta blocker for patients with pulmonary arterial hypertension: A single center experience

Moretti

Marra

D’Ascenzo

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…Moreover, the authors showed that in the HIVinfected patients, the impact of compliance with cardiovascular drugs on major adverse cardiac events in the long term (3.1 years) appeared to be reduced. 28 Another hypothesis concerns the fact that asymptomatic systolic and diastolic ventricular dysfunction remains frequent in HIV-infected patients, even in the HAART era, 29 and is only partially understood. The influence of antiretroviral drugs on the cardiovascular system is still a matter of debate, and accurate single-drug effect analyses remain challenging.…”

Section: One-year Prognosismentioning

confidence: 99%

Outcomes After Acute Myocardial Infarction in HIV-Infected Patients

et al. 2013

View full text Add to dashboard Cite

Background— We aimed to assess in-hospital case fatality and 1-year prognosis in HIV-infected patients with acute myocardial infarction. Methods and Results— From the PMSI (Program de Medicalisation des Systèmes d’informatique) database, data from 277 303 consecutive acute myocardial infarction patients hospitalized from January 1, 2005, to December 31, 2009, were analyzed. Surviving patients were followed up for 1 year after discharge. HIV-infected patients were compared with uninfected patients. Among the cohort, HIV-infected patients (n=608) accounted for 0.22%. All-cause hospital and 1-year mortality rates were lower in the HIV-infected group than in uninfected patients (3.1% versus 8.1% [ P <0.001] and 1.4% versus 5.5% [ P <0.001], respectively). From the database, we then analyzed a cohort derived from a matching procedure, with 1 HIV patient matched with 2 patients without HIV, based on age and sex (n=1824). Ischemic cardiomyopathy was more frequent in the HIV group (7.6% versus 4.2%, P =0.003). Hospitalization and 1-year mortality rates were similar in the 2 groups (3.1% versus 2.1% [ P =0.168] and 1.4% versus 1.7% [ P =0.642], respectively). However, at 12 months, hospitalizations for episodes of heart failure were significantly more frequent in HIV-infected than in uninfected patients (3.3% versus 1.4%, respectively; P =0.020). HIV infection, diabetes mellitus, history of ischemic cardiomyopathy, and undergoing percutaneous coronary intervention were associated in univariate analysis with occurrence of heart failure. By multivariable analysis, HIV infection (odds ratio 2.82, 95% confidence interval 1.32–6.01), diabetes mellitus, and undergoing percutaneous coronary intervention remained independent predictors of heart failure. Conclusions— The present study demonstrates that after acute myocardial infarction, HIV status influences long-term risk, although the short-term risk in HIV patients is comparable to that in uninfected patients.

show abstract

Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era

Abstract: Systolic and diastolic dysfunction represent a common finding in pauci symptomatic HIV-infected patients, regardless to HAART.

Cited by 128 publications

References 49 publications

An Update on Heart Transplantation in Human Immunodeficiency Virus–Infected Patients

An Update on Heart Transplantation in Human Immunodeficiency Virus–Infected Patients

Beta blocker for patients with pulmonary arterial hypertension: A single center experience

Outcomes After Acute Myocardial Infarction in HIV-Infected Patients

Contact Info

Product

Resources

About